[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352133-105":59,"doc-detail-352133-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pediatric-sarcomas-challenges-and-opportunities","Pediatric sarcomas - challenges and opportunities","","Pediatric sarcomas are rare, heterogeneous mesodermal malignancies affecting children from infancy through adolescence and young adulthood, and they remain difficult to treat with currently available therapies. Key biological features include quiet genomes, fusion oncoproteins, immune “cold” microenvironments, and extensive epigenetic deregulation. Progress is enabled by multifaceted research advances such as high-throughput screening, improved model systems, surfaceome profiling, and studies of oncogenic fusion condensates, alongside better bioinformatic access and innovative clinical trial frameworks.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pediatric-sarcomas-challenges-and-opportunities/352133/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pediatric-sarcomas-challenges-and-opportunities/352133.png","ImageObject",300,407,{"name":92,"@type":93},"hdkawk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What makes pediatric sarcomas particularly challenging to treat?","Question",{"text":112,"@type":113},"They are difficult to cure with currently available therapies, especially in metastatic or relapsed settings. Their biology is complex, including fusion oncoproteins, immune “cold” microenvironments, and broad epigenetic deregulation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which biological characteristics are highlighted for many pediatric sarcomas?",{"text":117,"@type":113},"Many are described as having quiet genomes, fusion oncoproteins, immune “cold” microenvironments, and vast epigenetic deregulation that drives diverse mechanistic pathways.",{"name":119,"@type":110,"acceptedAnswer":120},"What research and clinical opportunities are proposed to advance progress?",{"text":121,"@type":113},"The document points to advances like high-throughput screening, new model systems, surfaceome profiling, and studies of oncogenic fusion condensates. It also emphasizes improving access to bioinformatic data, using innovative clinical trial frameworks, and fostering interdisciplinary partnerships.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352133,1790151094,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Pediatric sarcomas: challengesand opportunities  \nYuan Gao, 1 Kelly M. Bailey,2 Samuel C. Blackman,3 John H. Bushweller,4,5 Shasha Chong,6 Kevin DeHond,7 Jolanta Grembecka,8 Mark E. Hatley,9 Cigall Kadoch,10,11,12 Angela N. Koehler,13 Corinne M. Linardic,14,15 Phil Renna,16,17 Frederic J. Reu,18 Miguel N. Rivera, 11,19,20  \nElizabeth A. Stewart,9 Bruce Stillman, 17 E. Alejandro Sweet-Cordero,21 Kimberly Stegmaier,10,11,22 Christopher R. Vakoc,17 and Lillian M. Guenther9  \n1Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio 44108, USA; 2Department of Pediatrics, Mayo Clinic Children’s, Mayo Clinic, Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota 55905, USA; 3Google Ventures, Mountain View, California 94043, USA; 4Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia 22908, USA; 5Department of Chemistry, University of Virginia, Charlottesville, Virginia 22908, USA; 6Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, USA; 7Friends of T.J. Foundation, Cold Spring Harbor, New York 11724, USA; 8Department of Pathology, University of Michigan, Ann Arbor, Michigan 48108, USA; 9Department of Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105, USA; 10Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA; 11Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142, USA; 12Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA; 13Department of Biological Engineering, Koch Institute for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA; 14Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina 27710, USA; 15Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina 27710, USA; 16Christina Renna Foundation, Inc., Lindenhurst, New York 11757, USA; 17Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA; 18Deciphera Pharmaceuticals, LLC., a member of ONO Pharma, Waltham, Massachusetts 02451, USA; 19Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA; 20Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA; 21Division of Hematology and Oncology, Department of Pediatrics, University of California, San Francisco, San Francisco, California 94158, USA; 22Division of Hematology/Oncology, Boston Children’s Hospital, Boston, Massachusetts 02115, USA  \nPediatric sarcomas are a heterogeneous group of rare mesodermal malignancies. These cancers, which affect children from infancy through adolescence and young adulthood, are in general challenging to treat with currently available therapies. Biologically, many are characterized by quiet genomes, fusion oncoproteins, immune“cold” microenvironments, and vast epigenetic deregulation that contributes to diverse and complex mechanistic drivers. Multifaceted advancementsin research strategies, including high-throughput screening, new model systems, surfaceome profiling, and study of oncogenic fusion condensates have led to new opportunities for understanding the biology of pediatric sarcomas. To continue to make progress for these difficult to treat cancers, it will be critical to continue to improve access to bioinformatic data, approach patient care using innovative clinical trial frameworks, and foster interdisciplinary partnerships among medicinal chemists, scientists, clinicians, advocates, and industry partners.  \n[Keywords: bone sarcomas; pediatric sarcomas; soft tissue sarcomas] Corresponding authors: [lillian.guenther@stjude.org](lillian.guenther@stjude.org), [yxg811@case.edu](yxg811@case.edu)[ ](yxg811@case.edu)Article published onli","cbCaiqWpZdy2VUvv","https://ap.wps.com/l/cbCaiqWpZdy2VUvv","pdf",269493,12,"English","# Overview\n## Biology and mechanistic complexity\n## Treatment challenges and disease burden\n## Opportunities from research advances\n## Patient care and collaboration","[{\"question\":\"What makes pediatric sarcomas particularly challenging to treat?\",\"answer\":\"They are difficult to cure with currently available therapies, especially in metastatic or relapsed settings. Their biology is complex, including fusion oncoproteins, immune “cold” microenvironments, and broad epigenetic deregulation.\"},{\"question\":\"Which biological characteristics are highlighted for many pediatric sarcomas?\",\"answer\":\"Many are described as having quiet genomes, fusion oncoproteins, immune “cold” microenvironments, and vast epigenetic deregulation that drives diverse mechanistic pathways.\"},{\"question\":\"What research and clinical opportunities are proposed to advance progress?\",\"answer\":\"The document points to advances like high-throughput screening, new model systems, surfaceome profiling, and studies of oncogenic fusion condensates. It also emphasizes improving access to bioinformatic data, using innovative clinical trial frameworks, and fostering interdisciplinary partnerships.\"}]","Pediatric sarcomas - challenges and opportunities | PDF",1790097839]